Boehringer Ingelheim | Sustainability Performance
A global healthcare company engaged in the research, development, and manufacturing of pharmaceuticals. It operates in various therapeutic areas, focusing on innovative treatments and animal health products to meet diverse medical needs.
1885
Germany
10,001+ employees
Pharmaceuticals
$100M - 500M in revenue
Not profitable
Sustainability Ranking & Industry Benchmark
#10740
Overall#467
in Germany#257
in PharmaceuticalsSustainability Maturity
Sustainability Intent
Overview
Environmental
Carbon certificatesGovernance
Targets
Controversy level
- Boehringer Ingelheim paid over USD 650 million settling thousands of Pradaxa bleeding death lawsuits in the US.
Carbon certificate projects
Reveal data for 3 credits
| Subsector | Country | Transaction date ⓘ | |||||
|---|---|---|---|---|---|---|---|
| 2021 | 2022 | 2023 | 2024 | 2025 | Total | ||
| ******* | ******* | - | ******* | ******* | ******* | ******* | ******* |
Powered by AlliedOffsets and illuminem
Sustainability targets and commitments
Reveal data for 1 credit
| Target | Year | Value | Scope | Baseline |
|---|
